Cellectar Biosciences
CLRB
5 hedge funds and large institutions have $353K invested in Cellectar Biosciences in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, reducing their positions, and 2 closing their positions.
12% less capital invested
Capital invested by funds: $403K → $353K (-$50K)
17% less funds holding
Funds holding: 6 → 5 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$49.2K |
| 2 |
Morgan Stanley
New York
|
+$24.6K |
| 3 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
+$8.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$35K |
| 2 |
Creative Planning
Overland Park,
Kansas
|
-$14K |
| 3 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAM
1
Cormorant Asset Management
Boston,
Massachusetts
| $145K | – | – | – |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $111K | +$49.2K | +6 | +75% |
|
|
3
Morgan Stanley
New York
| $50K | +$24.6K | +3 | +100% |
|
|
AIC
4
AWM Investment Company
New York
| $27K | – | – | – |
|
|
AIM
5
Acrospire Investment Management
Chicago,
Illinois
| $10K | +$8.2K | +1 | New |
|
|
WAM
6
Wealthspire Advisors (Maryland)
Potomac,
Maryland
| $3K | – | – | – |
|
|
BFA
7
BlackRock Fund Advisors
San Francisco,
California
| $2K | – | – | – |
|
|
MFS
8
MSI Financial Services
Springfield,
Massachusetts
| $2K | – | – | – |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $2K | – | – | – |
|
|
LTFS
10
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
|
11
UBS Group
Zurich,
Switzerland
| – | -$35K | -3 | Closed |
|
|
12
Creative Planning
Overland Park,
Kansas
| – | -$14K | -1 | Closed |
|
|
13
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$1K | – | – |
|
CLRB Hedge Fund Activity: Q3 2016 in Review
5 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q3 2016, worth a combined $353K — down 12% from $403K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CLRB and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 2 added.
The largest buyer was Vanguard Group, adding an estimated $49.2K. The largest seller was UBS Group, exiting entirely with an estimated $35K sold.
- 5 institutional investors held Cellectar Biosciences (CLRB) as of Q3 2016, down from 6 in Q2 2016.
- Funds reported $353K of Cellectar Biosciences stock for Q3 2016, down 12% quarter-over-quarter.
- 1 fund opened new Cellectar Biosciences positions in Q3 2016 and 2 closed out, a net change of -1 holder.
- The largest Cellectar Biosciences buyer in Q3 2016 was Vanguard Group, an estimated $49.2K added.
- The largest Cellectar Biosciences seller in Q3 2016 was UBS Group, an estimated $35K sold.
Based on aggregated 13F filings for Q3 2016.